**zVAD-induced autophagic cell death requires c-Src-dependent ERK and JNK activation and reactive oxygen species generation**

Szu-ying Chen,1 Ming-Chei Maa,2 Ling-Ya Chiu,1 Jang-Shiu Wang,1 Chung-Liang Chien3 and Wan-Wan Lin1,*

1Department of Pharmacology; College of Medicine; National Taiwan University; 2Graduate Institute of Molecular Systems Biomedicine; China Medical University; 3Department of Anatomy and Cell Biology; College of Medicine; National Taiwan University; Taiwan

**Key words:** caspase 8, autophagy, zVAD, c-Src, PARP, ROS

**Abbreviations:** ASK1, apoptosis signal-regulating kinase; Arg, autophagy-related; BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; BHA, butylated hydroxyanisol; CICD, caspase-independent cell death; DCFH-DA, 6-carboxy-2',7'-dichlorofluorescin diacetate; DED, death effector domains; DMSO, dimethyl sulfoxide; DR, death receptor; ECL, enhanced chemiluminescence; ERK, extracellular signal-regulated kinase; FACS, fluorescence-activated cell sorting; FBS, fetal bovine serum; FCCP, carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone; JNK, c-Jun-N-terminal kinase; LPS, lipopolysaccharide; 3-MA, 3-methyladenine; MAPK, mitogen-activated protein kinase; MEF, mouse embryonic fibroblasts; MNNG, N-methyl-N'-nitro-N-nitrosoguanidine; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium; NFκB, nuclear factor-kappaB; NOX, NADPH oxidase; PARP, poly(ADP-ribose) polymerase; PARG, poly(ADP-ribose) glycohydrolase; PE, phosphatidylethanolamine; PI3K, phosphatidylinositol 3-kinase; RIP, receptor interacting protein; ROS, reactive oxygen species; RT-PCR, reverse transcription-polymerase chain reaction; siRNA, small interfering RNA; TNF, tumor necrosis factor; TNFRI, tumor necrosis factor receptor type 1; TRAP2, TNF receptor-associated factor 2; WM, wortmannin; zVAD, benzyloxycarbonyl-Val-Ala-Asp

Introduction

Cell death can be largely divided into two classes, programmed cell death and necrosis. Programmed cell death can be further divided into several categories including apoptosis and autophagic death. Apoptosis is a cell-intrinsic mechanism for suicide regulated by cellular signaling pathways, morphologically characterized by caspase activation, cell shrinking, nuclear and cytoplasmic condensation, DNA fragmentation and formation of apoptosomes.1 The morphological hallmark of autophagy is a double-membrane vesicle called an autophagosome, which is formed in the cytosol, and encapsulates long-lived proteins, organelles and bulk cytoplasm. Through fusing with the lysosome, the contents in the autophagosome are degraded, and thus autophagy is an important mechanism to maintain homeostasis and to sustain cell viability under starvation conditions.2 However, recent studies have provided evidence that autophagy may lead to cell death.3 In contrast to apoptosis, necrosis has been traditionally thought to be a passive and accidental form of cell death, which is characterized by cytoplasmic swelling, irreversible plasma membrane

*Correspondence to: Wan-Wan Lin; Email: wwllaura1119@ntu.edu.tw
Submitted: 11/29/09; Revised: 03/22/10; Accepted: 04/01/10
Previously published online: www.landesbioscience.com/journals/autophagy/article/11945
damage, and organelle breakdown. The release of intracellular content after plasma membrane rupture is the cause of inflammation upon cell necrosis.

The activation of autophagy involves a series of steps: induction, expansion, completion, fusion, and degradation. The induction of autophagy requires Beclin 1 and its interacting partner, class III PtdIns3K, resulting in the generation of PtdIns(3,4,5)P3 on the endomembrane. In the induction stage, conversion of LC3 from LC3-I to LC3-II and then the recruitment of lipidated LC3-II to the phagophore are prerequisite steps for phagophore expansion. Once the autophagosome is completed, it then fuses with the lysosome and exhibits the punctate structure of the autolysosome. The sequestered cargo together with the LC3-II trapped in the lumen of the autophagosome is degraded within the autolysosome. Autophagy contributes to the elimination of misfolded proteins, and abnormal autophagy may lead to pathogenesis of some neurodegenerative disorder such as Alzheimer, Huntington and Parkinson diseases. The regulation of autophagy is also important during the progression of cancer. Autophagy may protect tumor cells from apoptosis in response to treatment with anticancer agents, but may be a mechanism for cell death, especially in tumor cells with defective apoptotic machinery.

Because caspase activation is necessary for apoptosis induction, benzoyloxycarbonyl-Val-Ala-Asp (zVAD), a cell-permeable pan-caspase peptide inhibitor that irreversibly binds to the catalytic site of caspase proteases and inhibits caspase-mediated apoptosis, is a widely used inhibitor in characterizing apoptotic cell death. However, recent studies have revealed a greater complexity of findings with zVAD, and suggest that caspases might be involved in other types of cell death. In the presence of zVAD to block apoptotic machinery, many death insults lead to necrotic cell death, which was termed caspase-independent cell death (CICD). No matter whether autophagy is involved or not, reactive oxygen species (ROS) were demonstrated to contribute to CICD.

In murine L929 fibrosarcoma cells, Lenardo’s group found that zVAD alone could lead to cell necrosis involving autophagosome formation and ROS production. Both actions of zVAD depend on caspase 8 inhibition. Moreover, they found the vacuolated cell formation is blocked by c-Jun siRNA, indicating that c-Jun N-terminal kinase (JNK) is involved in autophagic cell death induced by zVAD. Besides L929 cells, such autophagic CICD was also shown in lipopolysaccharide and zVAD co-treated macrophages. In that study, they found that such autophagy requires PARP1 activation, and involves a ROS-PARP1-autophagy pathway. Caspase-independent autophagy is not only detected in zVAD-treated cells where an apoptotic pathway cannot be achieved, but also in staurosporine, etoposide or photodamage-treated mouse embryonic fibroblasts (MEF) from Bax/Bak double knockout mice, which are resistant to apoptosis.

Even though autophagic cell death following caspase inhibition by zVAD has been identified in L929 fibrosarcoma, the molecular mechanism for ROS induction and JNK activation upon zVAD treatment is ambiguous. Although catalase degradation contributes to ROS accumulation in zVAD-treated L929 cells, we cannot exclude other sources for ROS elevation. Most importantly, how caspase inhibition links to autophagy formation has not been fully investigated. PARP1 activation is another issue not solved regarding its contribution in the autophagic cell death caused by zVAD in L929 fibrosarcoma. Therefore, in this study, taking L929 fibrosarcoma as a cell model, we elucidated the signaling pathways triggered by caspase inhibition and contributing to autophagosome formation.

**Results**

zVAD induces autophagic cell death in L929 fibrosarcoma. It has been reported that zVAD can induce autophagic cell death in L929 cells. Consistent with previous reports, we found that zVAD can induce autophagic features under electron microscopy observation. Compared with the control, zVAD induced autophagosome formation at 5 h and 10 h (Fig. 1A, parts VI, VII). Furthermore, some cells under zVAD treatment exhibited necrosis-like features, which were characterized by mitochondrial swelling (Fig. 1A, parts VII, VIII) and disruption of plasma membrane (Fig. 1A, parts II–IV). Before assessing the cell-death mechanism induced by zVAD in L929 cells, we first used biochemical and genetic approaches to confirm the death features of autophagy. Beclin 1 gene transcription, an initial step required for autophagosome formation, was determined by qPCR. We found that zVAD was able to induce a time-dependent increase of beclin 1 mRNA level, which was significantly increased at 3 h and peaked at 5 h (Fig. 1B). When Beclin 1 and Atg5 protein expression were suppressed using an siRNA approach, zVAD-induced cell death was attenuated as compared to the group of cells receiving control siRNA (Fig. 1C). Moreover, since LC3 conversion is a prerequisite for phagophore expansion and autophagosome formation, we measured the effect of zVAD on LC3-II expression. Figure 1D showed a marked appearance of LC3-II after 1 h incubation of zVAD. These results together demonstrate that autophagy is a mediator for zVAD-induced cell death in L929 fibrosarcoma.

JNK- and ERK-regulated ROS production from mitochondria contributes to zVAD-induced cell death. Previously, it was shown that zVAD-induced autophagic cell death is JNK- and ROS-dependent. Thus, we were interested in understanding the causal relationship of both death mediators, as well as the involvement or not of ERK and p38. Using antioxidant (trolax, which is a water soluble vitamin E analogue), ROS scavenger (BHA), mitochondrial respiratory chain inhibitors (rotenone, FCCP), and MAPK inhibitors (U0126, SP60015, SB203580), we found that zVAD-induced cell death can be attenuated by antioxidants, mitochondrial respiratory chain inhibitors, JNK inhibitor and MEK/ERK inhibitor, whereas SB203580 (p38 inhibitor) had no effect (Fig. 2A). We also detected the intracellular ROS level with the fluorescent dye DCFH-DA. Figure 2B showed that zVAD can induce intracellular ROS production in a time-dependent manner, and this effect was attenuated by the ROS scavenger BHA, and the JNK inhibitor SP600125. Likewise, trolax, U0126, but not SB203580, dramatically reduced the ROS production induced by zVAD (Fig. 2C). These results suggest that...
to find out if autophagy is upstream or downstream of ROS production under zVAD treatment, and if PARP1 is also involved in this event. To this end, we compared the death features of N-methyl-N'-nitro-N'-nitrosoguanidine (MNNG), a PARP1 activator, with zVAD. In L929 cells, MNNG (250 µM) treatment for 12 h could induce cell death. Pretreating cells with the PARP inhibitor DPQ (10 µM) could effectively diminish cell death in response to zVAD and MNNG (Fig. 3A), suggesting the involvement of PARP1 activation in death signals of both agents. Confirming this point, we found zVAD and MNNG could stimulate PARP1 activation as assessed by increasing PAR accumulation (Fig. 3B). In contrast to the rapid increase of PAR

Figure 1. zVAD induces autophagic cell death in L929 fibrosarcoma. (A) L929 cells were treated with zVAD (20 µM) for 5 or 10 h as indicated, and cells were collected and then prepared for electron microscopy (TEM) analysis as described in Materials and Methods. The photos shown in (V–VIII) are the amplification of (I–IV), respectively. The arrows indicate the appearance of autophagosomes, and arrowheads indicate the swelling mitochondria, which contain the double-membrane structures. (B) zVAD was added for the time periods as indicated. Total RNA was transcribed to cDNA and subjected to real-time PCR by using a specific primer for beclin 1. Values were normalized to β-actin gene expression, and expressed as fold of control. Data are mean ± S.E.M. from three independent experiments. *p < 0.05, indicating significant increase of beclin 1 mRNA by zVAD. (C) L929 cells were transfected with specific beclin 1 and Atg5 siRNA to knock down endogenous expression of beclin 1 and Atg5 or non-targeting siRNA as a control. After 48 h of transfection, cells were treated with zVAD (20 µM) for 12 h, and then cell viability was measured by MTT assay. When stimulating with indicated agents, we also collected cell lysates at the same time to determine the silencing efficiency by immunoblotting with anti-Beclin 1 and Atg5 antibodies. Data are mean ± S.E.M. from three independent experiments. *p < 0.05, indicating significant attenuation of zVAD-induced cell death by beclin 1 siRNA. (D) zVAD was added for the time periods as indicated, and total cell lysates were prepared and immunoblotted with LC3 and β-actin antibodies. Traces are representative from two independent experiments.

JNK and ERK signaling pathways are upstream of ROS increase. Next, we suspect that ROS production is derived from mitochondria, because BHA, a ROS scavenger specifically targeting mitochondria, is effective in blocking zVAD-induced ROS production. To verify this point, we used a mitochondria-specific dye MitoSox for ROS measurement. Results showed that zVAD still can induce mitochondrial ROS production in a time-dependent manner (Fig. 2D), indicating mitochondria is the major source for ROS production.

ROS production mediates PARP1 activation and autophagic cell death induced by zVAD. After observing that ROS and autophagy are involved in zVAD-induced necrosis, we attempted to find out if autophagy is upstream or downstream of ROS production under zVAD treatment, and if PARP1 is also involved in this event. To this end, we compared the death features of N-methyl-N'-nitro-N'-nitrosoguanidine (MNNG), a PARP1 activator, with zVAD. In L929 cells, MNNG (250 µM) treatment for 12 h could induce cell death. Pretreating cells with the PARP inhibitor DPQ (10 µM) could effectively diminish cell death in response to zVAD and MNNG (Fig. 3A), suggesting the involvement of PARP1 activation in death signals of both agents. Confirming this point, we found zVAD and MNNG could stimulate PARP1 activation as assessed by increasing PAR accumulation (Fig. 3B). In contrast to the rapid increase of PAR
Autophagy Volume 6 Issue 5

Activation is not sufficient to induce cell autophagy, and vice versa: it might be a downstream event of autophagy.

Furthermore, in order to understand the roles of autophagy and PARP1 in zVAD-induced ROS production, PARP1 and autophagic inhibitors were tested in the ROS productive response of zVAD. As shown in Figure 3C, L929 cells pretreated with trolox (1 mM), BHA (100 µM), U0126 (10 µM), SP600125 (10 µM) or SB203580 (3 µM) for 30 min, followed by zVAD (20 µM) incubation for 12 h. Cell viability was measured by MTT assay and expressed as percentages of control. Data are mean ± S.E.M. from three independent experiments. *p < 0.05, indicating significant attenuation of zVAD-induced cytotoxicity by trolox, BHA, rotenone, FCCP, U0126 and SP600125. (B) L929 cells were pretreated with or without BHA or SP600125 for 30 min, and then stimulated with zVAD (20 µM) for the indicated time periods. After treatment, cells were harvested and followed by intracellular ROS measurement. (C) L929 cells were pretreated with trolox (1 mM), BHA (100 µM), U0126 (10 µM), SP600125 (10 µM) or SB203580 (3 µM) for 30 min, and then stimulated with zVAD (20 µM). After 10 h incubation, cells were harvested, followed by measurement of intracellular ROS. Data are mean ± S.E.M. from three independent experiments. *p < 0.05, indicating significant attenuation of zVAD-induced ROS production by trolox, BHA, U0126 and SP600125. (D) zVAD (20 µM) was added for the time periods as indicated. After treatment, cells were harvested followed by measurement of mitochondrial ROS.

Figure 2. ROS production from mitochondria mediates zVAD-induced cell death. (A) L929 cells were pretreated with trolox (1 mM), BHA (100 µM), rotenone (Rot, 3 µM), FCCP (10 µM), U0126 (10 µM), SP600125 (10 µM) or SB203580 (3 µM) for 30 min, followed by zVAD (20 µM) incubation for 12 h. Cell viability was measured by MTT assay and expressed as percentages of control. Data are mean ± S.E.M. from three independent experiments. *p < 0.05, indicating significant attenuation of zVAD-induced cytotoxicity by trolox, BHA, rotenone, FCCP, U0126 and SP600125. (B) L929 cells were pretreated with or without BHA or SP600125 for 30 min, and then stimulated with zVAD (20 µM) for the indicated time periods. After treatment, cells were harvested and followed by intracellular ROS measurement. (C) L929 cells were pretreated with trolox (1 mM), BHA (100 µM), U0126 (10 µM), SP600125 (10 µM) or SB203580 (3 µM) for 30 min, and then stimulated with zVAD (20 µM). After 10 h incubation, cells were harvested, followed by measurement of intracellular ROS. Data are mean ± S.E.M. from three independent experiments. *p < 0.05, indicating significant attenuation of zVAD-induced ROS production by trolox, BHA, U0126 and SP600125. (D) zVAD (20 µM) was added for the time periods as indicated. After treatment, cells were harvested followed by measurement of mitochondrial ROS.

formation by MNNG, which is a PARP-1 activator, the onset of the zVAD response is slower. All these results suggest that PARP1 activation is involved in zVAD-induced autophagic cell death. To clarify the participation of autophagy in MNNG-induced cell death, we treated cells with two autophagic inhibitors which can achieve this action via inhibition of PtdIns3K.18 As expected, wortmannin (WT, 1 µM) and 3-methyladenine (3-MA, 10 mM) can effectively protect cells against zVAD-induced cell death. In contrast, both autophagic inhibitors have no effects on MNNG-induced cell death (Fig. 3A). These results suggest that PARP1 activation is not sufficient to induce cell autophagy, and vice versa: it might be a downstream event of autophagy.
Autophagy-mediated ROS production occurs downstream of autophagy, but upstream of PARP activation. (A) L929 cells were pretreated with DPQ (10 µM), 3-MA (10 mM) or wortmannin (WT, 1 µM) for 30 min, followed by zVAD (20 µM) or MNNG (250 µM) incubation for 12 h. Cell viability was measured by MTT assay and expressed as percentages of control. (B) zVAD (20 µM) and MNNG (250 µM) were added for the time as indicated, and total cell lysates were prepared and immunoblotted with PAR and β-actin antibodies. (C) L929 cells were pretreated with 3-MA or DPQ for 30 min, and then stimulated with zVAD (20 µM) for 10 h. After treatment, cells were harvested followed by measurement of intracellular ROS. (D) L929 cells were transfected with specific beclin 1 siRNA. After 48 h transfection, cells were treated with zVAD (20 µM) for 10 h, then intracellular ROS was measured. Data represent the mean ± SEM of three independent experiments. *p < 0.05, indicating significant attenuation of zVAD-induced cytotoxicity (A) and ROS production (C and D). (E) Cells were treated with BHA (100 µM), trolox (1 mM), SP600125 (10 µM) or U0126 (10 µM) for 30 min, followed by zVAD (20 µM) for the time as indicated, and total cell lysates were prepared and immunoblotted with PAR and β-actin antibodies.

silencing beclin 1 also achieved the inhibitory effect on zVAD-induced ROS production (Fig. 3D). These results together suggest that zVAD-induced ROS production occurs downstream of autophagy, but upstream of PARP1 activation. To further support previous suggestions, we analyzed the effects of antioxidants on zVAD-induced PAR formation. As shown in Figure 3E,
both trolox and BHA treatment abolished PAR induction caused by zVAD. Since ERK and JNK were shown to regulate zVAD-induced ROS production (Fig. 2C), we tested their roles in this aspect. Consistent with our scenario, U0126 and SP600125 reduced zVAD-induced PAR expression (Fig. 3E).

**c-Src is involved in zVAD-induced autophagic cell death.**

The relationship between c-Src and autophagy is still unclear. Previously it has been shown that insulin-induced cell swelling is sensed by integrins and thus transduces a signal for p38 activation via c-Src. This effect leads to the inhibition of autophagic proteolysis in rat liver cells. To understand if c-Src plays a crucial role in zVAD-induced autophagic cell death in L929 fibrosarcoma, we examined the effects of the specific c-Src inhibitor PP2. In Figure 4A, we found that PP2 treatment in a concentration-dependent manner confers cell protection against zVAD-induced cytotoxicity. Concomitantly, PP2 markedly reduced zVAD-induced ROS production in cytosol (Fig. 4B) and in mitochondria (Fig. 4C), suggesting that c-Src activity might mediate ROS-dependent autophagic cell death induced by zVAD. To further elucidate this event, we knocked down c-Src expression using an siRNA technique. Under efficient silencing of c-Src, we found that zVAD-induced cell death and ROS production were attenuated (Fig. 4D). These results highlight a new role played by c-Src in an autophagic cell death model of zVAD.

**c-Src mediates zVAD-induced JNK, ERK activation and autophagy.**

After observing the inhibitory effects of PP2 on ROS production and cell death, we were interested to understand the role of c-Src in zVAD-mediated upstream signaling cascades. Despite some studies that have demonstrated the roles of JNK and ERK in autophagy formation, and c-Src in the activation of both kinases, the function of c-Src in autophagy remains unknown. To clarify how c-Src crosstalked with ERK and JNK, we determined the effects of PP2 on zVAD-elicited JNK and ERK activation. Figure 5A showed that zVAD can induce a rapid and sustained activation of JNK and ERK within 4 h incubation. Moreover, both effects of zVAD were abolished by PP2, indicating c-Src is functioning upstream to JNK and ERK signaling. Next, to verify how c-Src, ERK and JNK activation contributes to autophagy, we determined the effects of kinase inhibitors on zVAD-induced beclin 1 gene expression. As shown in Figure 5B, zVAD-elicited beclin 1 gene transcription at 3 and 5 h was inhibited by PP2, U0126 and SP600125. These results suggest that c-Src activation by zVAD leads to ERK and JNK signal pathways and that the activation of both kinases in turn contributes to autophagy. We also used siRNA to knock down c-Src expression for further validation of its role in zVAD-induced autophagy, JNK and ERK signaling. Figure 5C showed that zVAD-induced LC3-II conversion, and JNK and ERK activation were inhibited after c-Src silencing. JNK and ERK inhibition after SP600125 and U0126 pretreatment, respectively, also blocked zVAD-induced LC3-II conversion (Fig. 5D). These results support the idea that c-Src mediates zVAD-induced JNK and ERK activation and autophagy.

**Caspase 8 inhibition leads to c-Src activation.** Recent studies identified caspase 8 as a c-Src substrate, and demonstrated that such tyrosine phosphorylation provides a new mechanism to inhibit caspase 8 activation. Moreover, novel enzymatic independent actions of caspase 8 in adhesion and epidermal growth factor-induced activation of the ERK pathway were reported. In order to link caspase 8 inhibition and c-Src activation upon zVAD treatment, we determined the binding condition of both proteins. Results of co-immunoprecipitation using c-Src antibody revealed that caspase 8 can bind to c-Src at resting state. Such constitutive binding was reduced after zVAD incubation for 10 and 30 min (Fig. 6A). zVAD treatment within 4 h does not change the expression levels of caspase 8 or c-Src (Fig. 6B). In addition, cleaved active caspase 8 was not detected following zVAD treatment. Intriguingly, zVAD is able to induce c-Src phosphorylation at Tyr 418, indicating the activation of this kinase (Fig. 6C).

**Discussion**

zVAD-induced autophagic necrosis in L929 fibrosarcoma. zVAD, a pan-caspase inhibitor, is widely used to determine whether cell death occurs by apoptosis. Nevertheless, to maintain cellular viability under proapoptotic conditions, recent studies have increased the complexity of findings with zVAD. In this context, zVAD alone or in the presence of extrinsic death receptor ligands, including TNFα, FasL, TRAIL and LIGHT, can drive necrotic cell death. Among these cases that were collectively defined as CICD, it is intriguing to note that zVAD alone is sufficient to induce L929 cell death, and in particular, unlike other necrosis induced by death receptor activation, it involves autophagosome formation. This unusual and cell-specific effect of zVAD in L929 cells becomes a valuable model to elucidate the link between caspase inhibition and autophagy formation.

In this study, in agreement with previous observations, our results showed that zVAD can exhibit autophagic features in L929 cells, such as autophagosome formation, LC3 cleavage and beclin 1 gene expression (Fig. 1A, B and D). All these features were markedly induced within 3–7 h, earlier than the necrotic cell death, which occurred at 10 h and was characterized morphologically by organelle swelling and disintegration, nuclear degradation and breakdown of the plasma membrane (Fig. 1A). Consistent with the previous notion that autophagy is involved in zVAD-induced cell necrosis, we confirmed this cell death was blocked by autophagy inhibitors (the class III PtdIns3K inhibitor 3-MA, and the classical PtdIns3K inhibitor wortmannin) as well as by knocking down beclin 1 and Atg5 (Figs. 1C and 3A). Nevertheless, Wu’s work in L929 cells shows that zVAD (10 µM) may block autophagy through the inhibition of cathepsin B activity, and autophagy may play a protective role in zVAD-induced necrotic cell death. In that work, 10 µM zVAD was used and it induced a rather delayed cell death as compared to our findings using 20 µM zVAD. We currently have no answer for this discrepancy, but we speculate that the switched role of autophagy in the control of cell survival and death might depend on the strength of the stimulus.

Mitochondrial ROS production is a downstream signal of autophagy. Several lines of evidence shown in this study support the essential role of mitochondria-derived ROS production
Figure 4. For figure legend, see page 8.
and found it could be inhibited by the autophagy inhibitor 3-MA (data now shown). Fifth, NADPH oxidase, which is responsible for TNFα-induced generation of O2•− in L929 fibrosarcoma,31 did not participate in the action of zVAD. Our results showed that the NADPH oxidase inhibitor DPI (1 µM) is not able to inhibit zVAD-elicited ROS production (data not shown). Therefore, we conclude that under zVAD treatment ROS production in L929 cells from mitochondria is downstream of autophagy, and mediates cell necrosis. In this aspect, an amplification loop between autophagy formation and ROS production might exist.

**Figure 4 (See previous page).** c-Src is involved in zVAD-induced autophagic cell death. (A) L929 cells were pretreated with PP2 at concentrations indicated for 30 min, followed by zVAD (20 µM) stimulation. After 12 h incubation, cell viability was measured by MTT assay. (B) L929 cells were pretreated with PP2 (10 µM) for 30 min, followed by zVAD (20 µM) stimulation for 10 h, and then cells were harvested for intracellular ROS measurement. (C) L929 cells were pretreated with PP2 (10 µM) for 30 min, followed by zVAD stimulation at the indicated time periods, and then cells were harvested for mitochondrial ROS measurement. The panel at the right hand shows the raw data. (D) L929 cells were transfected with Src-targeted siRNA, followed by stimulation with zVAD (20 µM). Cell viability (left) and intracellular ROS (right) were determined. Upon stimulating with the indicated agents, cell lysates were collected to determine the silencing efficiency by immunoblotting with anti-Src antibody. Data represent the mean ± SEM of three independent experiments. *p < 0.05, indicating significant attenuation of zVAD-induced cytotoxicity and ROS production.

**Figure 5.** c-Src mediates JNK and ERK activation caused by zVAD. (A) L929 cells were treated with PP2 and zVAD for the indicated time periods. Cell lysates were harvested for immunoblotting of JNK-p, JNK1, ERK-p and ERK2. (B) Cells were treated with PP2 (10 µM), U0126 (10 µM) or SP600125 (10 µM) for 30 min, and then stimulated with zVAD (20 µM). After 3 or 5 h incubation, cells were harvested, followed by measurement of beclin 1 mRNA. (C) L929 cells were transfected with specific c-Src siRNA to knock down endogenous expression of c-Src or non-targeting siRNA as a control. After 48 h of transfection, cells were treated with zVAD (20 µM) for the indicated time. Cell lysates were harvested for immunoblotting of JNK-p, JNK1, ERK-p, ERK2, beclin 1 and β-actin. (D) Cells were treated with SP600125 (10 µM) or U0126 (10 µM) for 30 min, and then stimulated with zVAD (20 µM) for the indicated time. Cell lysates were harvested for immunoblotting of LC3 and β-actin.

downstream of autophagy in zVAD-induced cell necrosis. First, there is a correlated attenuation of zVAD-induced cytotoxicity (Fig. 2A) and ROS production (Fig. 2B and C) by ROS scavengers (trolox, BHA). Second, the autophagic inhibitor (3-MA) (Fig. 3C) and siRNA to beclin 1 (Fig. 3D) can effectively reduce ROS induction. Third, inhibitors of the mitochondrial respiratory chain (i.e., rotenone and FCCP) remarkably inhibit ROS production and cell death, suggesting mitochondria are the major source for the zVAD-elicited ROS increase. Fourth, we detected a mitochondrial ROS increase under zVAD stimulation (Fig. 2D) and found it could be inhibited by the autophagy inhibitor 3-MA (data now shown). Fifth, NADPH oxidase, which is responsible for TNFα-induced generation of O2•− in L929 fibrosarcoma,31 did not participate in the action of zVAD. Our results showed that the NADPH oxidase inhibitor DPI (1 µM) is not able to inhibit zVAD-elicited ROS production (data not shown). Therefore, we conclude that under zVAD treatment ROS production in L929 cells from mitochondria is downstream of autophagy, and mediates cell necrosis. In this aspect, an amplification loop between autophagy formation and ROS production might exist. It has
been demonstrated that starvation induces complex formation between class III PtdIns3K and Beclin 1, which in turn, together with other signals, leads to a local rise in H$_2$O$_2$ in the vicinity of mitochondria. This oxidative signal inactivates Atg4, thereby promoting lipidation of Atg8, an essential step in the process of autophagy.32

However, unlike the case in zVAD-treated L929 cells, TNFα, which also induces ROS-dependent necrosis in L929 cells,35 does not trigger autophagy formation based on morphological and biochemical analyses (data not shown). MNNG action is another case that can induce ROS production, but not autophagy formation (data not shown). Moreover, 3-MA and wortmannin have no effects on MNNG- (Fig. 3A), TNFα- and H$_2$O$_2$-induced cytotoxicity (data not shown). Therefore, even though autophagy is induced by ROS in various pathophysiological conditions,12,32,34 such as during nutrient starvation, mitochondrial toxins, ischemia and reperfusion, it is not a general phenomenon. At least in L929 fibrosarcoma, it does not happen in the treatment with MNNG, TNFα and H$_2$O$_2$. Alternatively the autophagy induction by zVAD might rely on an additional specific upstream regulating signal.

c-Src-dependent ERK and JNK are required for autophagy formation. Intriguingly, our study also showed a novel enzymatic activity-independent action of caspase 8 in Src, JNK and ERK activation in L929 cells. It has been reported that MAPK-signaling pathways are able to modulate autophagy in different manners. ERK1/2 could phosphorylate G interacting protein (GAIP) and stimulate autophagy.20 Conversely, amino acids stimulate the sustained phosphorylation of GAIP at Ser259, which is involved in the negative regulation of Raf-1, and thus inhibits Ras/Raf-1/ERK1/2-mediated autophagy.35 In contrast, it was shown that p38 might limit the constitutive autophagy activity by impeding the fusion of autophagosomes and lysosomes. This blockade, however, could be relieved by transiently activated ERK induced by autophagic stimuli such as starvation.36 The relationship between JNK and autophagy has also been reported recently. In this context, ER stress induced IRE1-JNK activation was demonstrated to be required for autophagosome formation.21 Subsequent studies further identified the molecular links between JNK and autophagy. Phosphorylation of Bcl-2, which disrupts the Bcl-2-Beclin 1 complex in turn leading to autophagy, was demonstrated.55,56 Except Bcl-2 phosphorylation, JNK-mediated beclin 1 expression and p53 phosphorylation were demonstrated to contribute to autophagic cell death in cancer cells.39 Moreover, since Src has been reported in the upstream signaling of MAPKs, including ERK and JNK, our results suggest the necessity of ERK and JNK for zVAD-induced autophagy, and provide evidence that Src is a key player for the activation of both kinases.

**Caspase 8 inhibition releases c-Src activation under zVAD treatment.** Currently, the relationship between Src and autophagy is still unclear. Previously, Schliess et al. showed that insulin-induced cell swelling is sensed by integrins, which transduce signaling via Src into p38 activation, and lead to inhibition of autophagic proteolysis in rat liver cells.19 Interestingly, here we found Src is involved in zVAD-induced autophagic cell death. Src inhibitor (PP2) pretreatment can protect L929 cells against zVAD-induced cytotoxicity (Fig. 4A) and intracellular ROS production (Fig. 4B and C), but it has no effects on the similar responses caused by TNFα or MNNG in L929 cells (data not shown). Consistently, when silencing c-Src with an siRNA approach, both zVAD-induced cell death and ROS production are attenuated, while it still has no effect on TNFα-induced ROS production (data not shown). Such an insulin-specific difference might be due to the distinct cell death pathways stimulated by these inducers. TNFα and MNNG, as we mentioned above, induce necrosis without containing autophagy in L929 cells. Therefore, it is suggested that c-Src may mediate signaling cascades responsible for autophagosome formation.

A previous study has shown the involvement of caspase 8 inhibition in zVAD-induced autophagic cell death in L929 cells.10 One mechanism possibly contributing to this event is due to the accumulation of Beclin 1, a novel caspase substrate, leading to an increase in autophagy.40 Despite this, Finlay and Vuori (2007) strikingly demonstrated a novel enzymatic-independent action of procaspase 8. They showed that in neuroblastoma cells upon EGF stimulation, procaspase 8 forms a complex with c-Src via its death effector domain.41 Subsequently c-Src-mediated phosphorylation of caspase 8 at Tyr380 leads to caspase inhibition,23,24 and then converts caspase 8 from a pro-apoptotic factor to a novel signaling molecule that can regulate cell adhesion and motility.25,26 Extending the above findings showing that c-Src
activation provides a new role for caspase 8 in signal transduction, we surprisingly observed the binding of c-Src and caspase 8 under resting conditions in L929 fibrosarcoma (Fig. 6A). Moreover, it is interesting to note that such an interaction is reduced when caspase 8 is in an inhibitor-bound inactive state, leading to the dissociation and activation of c-Src (Fig. 6A and C). Therefore, our study again strengthens the crucial crossregulation between caspase 8 and c-Src, and provides an additional mechanism to limit c-Src activation at the basal state. According to previous findings as well as ours, caspase 8 is a new signaling adaptor for c-Src under resting conditions, and it can initiate catalytic activity-independent signaling pathways. In L929 fibrosarcoma, upon casapse inhibitor binding to caspase 8, recruited c-Src can be released for activation and then initiation of autophagic cell death. Nevertheless in some EGF-stimulated cancer cells, c-Src activation leads to phosphorylation of the recruited caspase-8, preventing its autocatalysis and switching its function as an adaptor for cell migration and adhesion. In L929 cells, we suggest the binding between c-Src and caspase 8 can be modulated by the caspase 8 conformation; possibly the binding of zVAD to the catalytic groove of procaspase 8 results in conformational changes and hinders the accessibility of c-Src to the death effector domain of procaspase 8.

PARP1 mediates ROS-dependent necrosis. PARP1 hyperactivation-induced necrosis has been implicated in several pathophysiological conditions. Overactivation of PARP1 results in unregulated PAR synthesis and widespread cell death. Previous studies, in most cases using MNNG as a potent PARP1 activator, have revealed that the generation of PAR can trigger intracellular ATP depletion, mitochondrial dysfunction, AIF release, calpain activation and eventually caspase-independent necrotic cell death. Even though it has been demonstrated that PARP activation could modulate autophagic cell death, the signaling pathway between PARP and autophagy is unclear. Currently bidirectional interactions between ROS production and PARP1 activation have been documented. In this aspect, some studies showed that ROS production can trigger PARP1 activation followed by autophagic cell death. Vice versa, PARP1 activation also was reported to induce ROS generation from mitochondria. In this study, we found that the PARP1 inhibitor (DPQ) can attenuate cell death induced by zVAD and MNNG (Fig. 3A), but not by TNFα (data not shown), suggesting PARP1 activation is also involved in zVAD-induced autophagic cell death in L929 cells. Conversely, DPQ has no effect on zVAD-induced ROS production (Fig. 3C), while it can block that induced by MNNG (data not shown). These findings suggest that upon zVAD stimulation of L929 cells, PARP1 activation is a downstream event of ROS production. Recent studies also have implicated the close relationship between ER stress and autophagy. ER stress-induced IRE1-JNK activation is required for autophagosome formation. Based on this, we examined whether an ER stress response occurs in zVAD-treated cells. We did not observe any features of ER stress, for example GRP78 and CHOP induction, in zVAD-treated L929 cells (data not shown).

In summary, we propose signaling pathways for zVAD-induced cell death in L929 cells. zVAD-induced inhibition of caspase 8 can dissociate and release c-Src for activation, which then transduces signals to ERK and JNK. The activation of both MAPks in turn sequentially triggers autophagy, ROS accumulation, PARP1 activation and necrotic cell death.

Materials and Methods

Cell culture. Murine L929 fibrosarcoma cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (v/v), 100 U/ml penicillin, 100 μg/ml streptomycin, and incubated at 37°C in a humidified atmosphere of 5% CO₂ in air.

Reagent. DMEM (12100-046), FBS (04001-1A), penicillin and streptomycin (03031-1B) were purchased from Gibco BRL. Polyclonal antibodies specific for ERK2 (sc-154) and JNK1 (sc-474) horseradish peroxidase-conjugated anti-mouse (sc-269) and anti-rabbit (sc-2004) antibodies were purchased from Santa Cruz Biotechnology. Polyclonal antibody specific for β-actin (MAB1501) was obtained from Upstate. PP2 (529573), U0126 (662005), SB203580 (559389), trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) (648471), SP600125 (420119), and wortmannin (681675) were obtained from Calbiochem. Phosphorylated antibodies of ERK (Thr202/Tyr204, 9101) and JNK (Thr183/Tyr185, 9251) were purchased from Cell Signaling Technology. Beclin 1 (612112) and PAR (5181) antibodies were obtained from BD Pharmingen. 3- Methyladenine (3-MA, M9281), carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone (FCCP, C2920), rotenone (R8875), zVAD-fluoromethylketone (zVAD-FMK, H8787), butylated-hydroxyanisol (BHA, B6655), 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazoliumbromide (MTT, M2128), and 2’-7’-dichloro-dihydrofluorescein diacetate (DCFH₂-DA, D6883) were from Sigma-Aldrich. N-methyl-N’-nitro-N-nitrosoguanidine (MNNG, O2392) was purchased from Chem Service. LC3 (PM036) antibody was purchased from MBL. MitoSOX™ (M36008) was purchased from Invitrogen-Molecular Probes. Atg5 antibody (GTX102361) was purchased from Gentex.

Measurement of cell viability by MTT assay. Cells (10⁴/ml) grown in 96-well plates were incubated with the indicated drugs. For MTT assay, MTT (5 mg/ml) was added for 1 h, then the culture medium was removed; the formazan granules generated by live cells were dissolved in 100% DMSO and shaken for 10 min. The OD at 550 nm and 630 nm was measured using a microplate reader. The net absorbance (OD550 minus OD630) indicates the enzymatic activity of mitochondria and implicates cell viability.

RNA interference. The siRNA duplexes specific for mouse c-Src (LU-040877-00-0002), beclin 1 (L-055895-00-0005) and Atg5 (L-064838-00-0005) were obtained from Dharmacon RNA Technologies. The siRNA contained four RNA sequences and/or content comparable to that of the functional siRNA but lacking specificity for known gene targets. The 100 nM RNAi was transfected by means of MicroPorator (Promega), and the
condition was PulseVoltage (V):1600; Pulse Width (ms):10; PulseNumber: 4. To achieve gene silencing, we transfected the cells with the siRNA for 48 h and followed by the drug treatment; then the gene silencing effects were evaluated by western blot analysis.

**Immunoblot analysis and immunoprecipitation.** After stimulation, cells were lysed in 1% Triton X-100 lysis buffer (20 mM Tris-HCl, pH 7.5, 125 mM NaCl, 1% Triton X-100, 1 mM MgCl₂, 25 mM β-glycerophosphate, 50 mM NaF, 100 μM Na₂VO₄, 1 mM PMSF, 10 μg/ml leupeptin, and 10 μg/ml aprotinin). The cell lysates were resolved by SDS-PAGE and analyzed by western blotting with specific antibodies. To determine the binding between caspase 8 and c-Src, cells treated with zVAD were washed twice with PBS, lysed in 500 μl RIPA lysis buffer (containing 150 mM NaCl) and centrifuged at 14,000 rpm, at 4°C for 30 min. The supernatant fraction was collected and pre-cleaned by normal IgG and 10 μl protein A/G-agarose beads for 1 h at 4°C. After centrifugation, supernatant was incubated with c-Src antibody at 4°C with rocking overnight and then 10 μl protein A/G-agarose beads were added and the sample was rotated at 4°C for another 30 min. The immunocomplexes were washed three times with cold lysis buffer (containing 150 mM NaCl) and twice with 300 mM NaCl-containing lysis buffer. The precipitated complexes were added to 50 μl 2X Laemmli sample buffer, and the samples were heated to 95°C for 5 min. After centrifugation, the sample supernatants were resolved by 10% SDS-PAGE, and then the proteins detected by immunoblotting with specific primary antibody.

**Cytosolic and mitochondrial ROS detection.** For measuring cytosolic and mitochondrial ROS, we used DCFH-DA and MitoSOX™, respectively. DCFH-DA can readily enter cells and be cleaved by esterase to yield a polar, nonfluorescent product, leaving the set without the final cut. Oncogene 2008; 27:6452-61.

**Electron microscopy detection of autophagosomes.** Cells were collected and fixed with 4% paraformaldehyde in 0.1 M cacodylate buffer at 4°C overnight. Cells were then rinsed with cacodylate buffer and post-fixed with 1% osmium tetroxide in 0.1 M cacodylate buffer and subsequently dehydrated in a graded series of ethanol (75%, 85%, 95% and 100%), and embedded in an Epon-araldite mixture. After the resin had solidified, the plastic culture dish was broken up to release the resin containing the embedded cells. Specimens were sectioned with a Diatome diamond knife on a Reichert Ultracut E ultramicrotome (Leica). Ultrathin sections were stained with uranyl acetate and lead citrate and viewed with an H-7100 electron microscope (Hitachi).

**Statistical evaluation.** Values are expressed as the mean ± S.E.M. of at least three experiments. Analysis of variance was used to assess the statistical significance of the differences, with a p value of <0.05 being considered statistically significant.